NCT00207311View on ClinicalTrials.gov

Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Fatty LiverHepatitis C
Interventions
DRUG

Xenical, Pegasys, Copegus

Xenical 120mg three times daily for 36 weeks or xenical placebo (Arm 1). Pegasys 180 mcg weekly for 48 weeks. Ribavirin daily for 48 weeks.

BEHAVIORAL

Xenicare Program

Xenicare program for 36 weeks.

Trial Locations (1)

78234

Brooke Army Medical Center, Fort Sam Houston

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

The Geneva Foundation

OTHER

lead

Brooke Army Medical Center

FED

NCT00207311 - Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus | Biotech Hunter | Biotech Hunter